Skip to main content

Table 4 Univariate and multivariate analyses of factors affecting risk of radiation pneumonitis of Grade 2 or more and discontinuation of durvalumab Univariate analysis

From: Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Variables   N 6 M cumulative incidence of G2RP (%) p value 6 M cumulative incidence of discontinuation of Durvalumab due to G2RP (%) p value  
Gender Male 37 48.7 0.038 21.6 0.03  
  Female 19 18.6   0.0   
Pulmonary Fibrosis Score ≥ 2 10 90.0  < 0.001 60.0  < 0.001  
  0–1 46 28.3   4.3   
Smoking history Present 45 46.5 0.031 17.8 0.14  
  Never 11 9.0   0.0   
Lung V40 ≥ 10% 30 57.3 0.011 20.0 0.21  
   < 10% 26 16.7   7.7   
Initial PTV ≥ 398 ml 24 58.3 0.024 25.0 0.048  
  < 398 ml 32 23.8   6.3   
Multivariate analysis
Variables   HR 95% CI p value HR 95% CI p value
Pulmonary Fibrosis Score ≥ 2 7.83 3.38–18.13  < 0.001 5.89 1.53–22.68  < 0.001
Lung V40 ≥ 10% 3.17 1.09–9.19 0.034    
Initial PTV      2.62 0.71–9.71 0.15
  1. Lung V40 percentage of the lung volume exceeding x Gy, Lung Vs5 volume of the lung received less than 5 Gy, HR hazard ratio, PTV planning target volume